

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 MARCH 2024 ERRATUM

(1) This Erratum removes the Premium for one of the new 60-day dispensing items for **Eprosartan** in the 1 March 2024 Schedule.

General Pharmaceutical Benefits

▪ EPROSARTAN

Authority required

Adverse effects occurring with all of the base-priced drugs

Clinical criteria:

- The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.

Authority required

Drug interactions occurring with all of the base-priced drugs

Clinical criteria:

- The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.

Authority required

Drug interactions expected to occur with all of the base-priced drugs

Clinical criteria:

- The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.


Authority required

Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance

Clinical criteria:

- The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.

eprosartan 600 mg tablet, 28

13861M	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
	2	5	..	*41.55	31.60	Teveten [GO]